CSRXP STATEMENT ON U.S. SENATE REINTRODUCTION OF THE ETHIC ACT
Coalition Commends Bipartisan Group of Lawmakers for Commitment to Cracking Down on Big Pharma’s Egregious Abuse of the U.S. Patent System
Washington, D.C. – The Campaign for Sustainable Rx Pricing (CSRxP) issued the following statement on Wednesday on the reintroduction of the “Eliminating Thickets to Improve Competition (ETHIC) Act” in the U.S. Senate. A U.S. House companion of the bill was introduced in May.
“CSRxP commends U.S. Senators Welch (D-VT), Hawley (R-MO), Klobuchar (D-MN), U.S. Representative Jodey Arrington (R-TX-19) and all the sponsors of the ETHIC Act for their commitment to holding Big Pharma accountable for egregious abuse of the patent system that keeps prescription drug prices high for American patients,” said CSRxP executive director Lauren Aronson. “Anti-competitive tactics, like patent thicketing, enable Big Pharma to extend monopoly pricing on blockbuster products, costing patients, taxpayers and the U.S. health care system billions of dollars each year. Fostering greater competition by cracking down on Big Pharma’s patent abuse will bring more affordable alternatives to the market earlier and help lower prices for patients.”
Read more about Big Pharma’s patent abuse HERE.
Read more on bipartisan, market-based solutions to hold Big Pharma accountable HERE.
###
